CARMAT announced it has implanted its Aeson® artificial heart in 100 patients, a significant milestone reached with the 99th and 100th implants occurring simultaneously in French university hospitals. This achievement marks a rapid acceleration in implantations, with the second set of 50 implants occurring in just over a year, compared to the decade it took to reach the first 50. This acceleration stems from the expanding use of the Aeson® heart across Europe and increasing acceptance by medical professionals.
The rapid increase in Aeson® implants demonstrates the growing demand for effective treatments for advanced heart failure, a condition with limited options. The quickening pace of adoption suggests the device is successfully integrating into standard clinical practice, validating its potential to address a significant unmet medical need. This positive trajectory directly supports CARMAT’s goal of doubling sales in 2025.
CARMAT achieved 50 implants between 2013 and the end of 2023. The subsequent 50 implants were performed in just over a year, marking a substantial increase in adoption rate. This accelerated growth aligns with the company’s sales projections and solidifies the Aeson® artificial heart’s position as a viable treatment option.
This milestone signifies a turning point for CARMAT and the field of advanced heart failure treatment. The accelerated adoption of the Aeson® heart indicates a promising future for the device and offers hope for a substantial improvement in the lives of patients with this life-threatening condition. The continued growth in implants will likely drive further research and development, potentially leading to broader applications and improved outcomes for patients with end-stage biventricular heart failure.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
